Go Back   HER2 Support Group Forums > Clinical Trials
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Thread Tools Display Modes
Old 04-13-2004, 05:01 AM   #1
Posts: n/a
A breast-cancer vaccine based on a peptide of human epidermal growth factor receptor 2 (HER2/neu) was demonstrated to be safe and effective in causing an immune response as reported on March 31 2004 at the American Association of Cancer Research (AACR) 95th Annual Meeting.

The vaccine is based on the E75 peptide which is an immunogenic cytotoxic T lymphocyte (CTL) epitope from the HER2/neu protein that is over-expressed in breast cancer. The clinical study run by the United States Army's Clinical Breast-Care Project (CBCP) has enrolled 34 node-positive women whose tumors express HER2/neu; 20 of those are controls. The cross-link below will take you to the AACR news release.

The non-military portion of the CBCP's HER-2 vaccine project is being administered by Windber Medical Center located in Somerset County Pennsylvania (www.windbercare.com). It is my understanding that Windber is currently recruiting women for its HER-2 vaccine clinical trial. To participate you must test positive for the presence of the human leucocyte antigen A2 (HLA-A2) in your blood. You can contact Maureen at 1-866-253-4703 (toll free) for more information.
  Reply With Quote

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Forum Jump

All times are GMT -7. The time now is 10:19 AM.

Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2020, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007
free webpage hit counter